Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenstrรถm's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT01691807
- Locations
- ๐บ๐ธ
Novartis Investigative Site, Morgantown, West Virginia, United States
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Gruppo Italiano Studio Linfomi
- Target Recruit Count
- 60
- Registration Number
- NCT01686386
- Locations
- ๐ฎ๐น
U. O. C. Ematologia - Azienda Ospedaliera Cosenza, Cosenza, Italy
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 670
- Registration Number
- NCT01678430
- Locations
- ๐ฌ๐ง
Derriford Hospital, Plymouth, Devon, United Kingdom
๐ฌ๐งTorbay Hospital, Torquay, Devon, United Kingdom
๐ฌ๐งDorset County Hospital, Dorchester, Dorset, United Kingdom
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01671904
- Locations
- ๐บ๐ธ
Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธUniversity of California San Diego Medical Center, La Jolla, California, United States
๐ซ๐ทHopital Saint Eloi, Montpellier, France
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
- Conditions
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: Anti-Thymocyte GlobulinDrug: Bendamustine HydrochlorideDrug: Fludarabine PhosphateBiological: Inotuzumab OzogamicinDrug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationBiological: RituximabDrug: Tacrolimus
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01664910
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01661881
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 71
- Registration Number
- NCT01657331
- Locations
- ๐บ๐ธ
Center for Lymphoid Malignancies at CUMC, New York, New York, United States
๐จ๐ฆPrincess Margaret Hospital, Toronto, Ontario, Canada
๐จ๐ฆBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01649622
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT01626352
- Locations
- ๐บ๐ธ
Woodlands Medical Specialists, Pensacola, Florida, United States
๐บ๐ธFlorida Cancer Specialists North, Saint Petersburg, Florida, United States
๐บ๐ธSpace Coast Cancer Center, Titusville, Florida, United States
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 578
- Registration Number
- NCT01611090
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.